ESGREV
@esgrev-escmid.bsky.social
📤 128
📥 182
📝 10
ESCMID Study Group for Respiratory Viruses
pinned post!
This is the
@bsky.app
🦋 account for ESGREV, the Respiratory Virus Study Group of ESCMID, the European Society for Clinical Microbiology and Infectious Diseases. Follow us for
#research
and
#science
news!
@escmid.bsky.social
about 1 year ago
0
8
3
reposted by
ESGREV
Institut Pasteur | 130 years of biomedical research
3 months ago
🦠 Measles is back. Cases have exploded in 2025 in France, UK, US & Europe due to falling vaccine coverage. The MMR vaccine is ~100% effective with 2 doses. It's saved 94M lives since 1974. Measles isn't just for kids – 34% of US cases were adults over 20.
www.pasteur.fr/en/research-...
#Measles
loading . . .
Three questions about measles: why is it on the rise, is the vaccine effective, and can you catch it at any age?
A few years ago, measles seemed to be on the verge of being eradicated in many countries. The recent rise in cases raises several questions. Why is measles making a comeback? Is the measles, mumps and...
https://www.pasteur.fr/en/research-journal/news/three-questions-about-measles-why-it-rise-vaccine-effective-and-can-you-catch-it-any-age
0
13
8
reposted by
ESGREV
International Society of Antimicrobial Chemotherapy
3 months ago
🌍 World AMR Awareness Week (#WAAW2025) 🎥 Dr Teske Schoffelen introduces the Abx Guide—a free, open-access database that compiles evidence on pathogen-directed antibiotic treatment. ▶️ Watch:
youtu.be/XpN_fRG7pCk
@heiman-wertheim.bsky.social
@souhakanj.bsky.social
loading . . .
WAAW 2025 | ISAC Abx Guide
YouTube video by ISAC / APUA
https://youtu.be/XpN_fRG7pCk
0
3
3
reposted by
ESGREV
European Centre for Disease Prevention and Control
3 months ago
DON'T MISS IT! From Resistance to Resilience: healthcare workers leading the change. Join public health professionals, academia, patients' and NGO's representatives and let's talk about the ways to
#KeepAntibioticsWorking
!
#EAAD2025
online event starts at 1PM CET! Register:
bit.ly/EAAD2025Regi...
1
4
9
reposted by
ESGREV
Eurosurveillance journal
3 months ago
#Respiratory
syncytial virus can cause severe illness especially in infants Data from Belgium, Portugal & Spain show that
#immunisation
of
#children
after birth with long-acting monoclonal antibodies 📉 the risk of
#hospitalisation
due to
#RSV
infection by ~80%
#IDSky
#EpiSky
#PedSky
#MedSky
🛟🧪
loading . . .
Study in Europe: monoclonal antibodies effectively prevent respiratory syncytial virus in infants
Respiratory syncytial virus can cause severe illness especially in young infants. A new study published in Eurosurveillance shows that immunisation of children after birth reduced the risk of hospital...
https://www.eurekalert.org/news-releases/1105935
0
8
6
reposted by
ESGREV
European Centre for Disease Prevention and Control
3 months ago
You can also find more information about
#RSV
on the European Vaccination Information Portal -
#EVIP
in YOUR language! Check it out here:
vaccination-info.europa.eu/en/rsv
#UnitedInProtection
#VaccinesSaveLives
#VaccinesWork
#ChildHealth
#PublicHealth
loading . . .
RSV
Key facts on RSV symptoms, complications, risk factors, how it spreads, prevention, vaccination and treatment.
https://vaccination-info.europa.eu/en/rsv
0
3
5
reposted by
ESGREV
European Centre for Disease Prevention and Control
3 months ago
This winter, raising awareness among healthcare workers & following national recommendations will remain essential to reducing the burden of RSV on infants. Press release:
bit.ly/4qSWLex
Rapid scientific advice:
bit.ly/4hTTNSG
Living systematic review:
bit.ly/4hVQLxz
#IDsky
#EpiSky
loading . . .
Protecting infants against respiratory syncytial virus this winter — ECDC issues advice
ECDC has issued a rapid scientific advice on effective ways to mitigate the impact of RSV disease in infants through immunisation interventions.
https://bit.ly/4qSWLex
1
5
6
🛎️
add a skeleton here at some point
4 months ago
0
0
0
reposted by
ESGREV
Zentrum für Klinische Studien (ZKS) Köln
4 months ago
🎓 Jetzt anmelden! Vom 01.–05.12.2025 bietet die Akademie des ZKS Köln wieder den Kurs für Studienkoordination an – als virtuelle Präsenzschulung. Für Study Nurses & Interessierte, die ins Studienmanagement einsteigen wollen. 👉 zks.uni-koeln.de/akademie/kurs-fuer-studienkoordination
0
2
3
reposted by
ESGREV
ESWI
4 months ago
📜 At
#ESWI2025
Maria Zambon traces the history of how we understand pandemics — from religious interpretations to the rise of rational, evidence-based therapeutics A fascinating look at how science reshaped our view of disease and response🧠
#PublicHealth
#Pandemic
#History
0
6
3
reposted by
ESGREV
IDWeek
4 months ago
Immunization against respiratory syncytial virus delivered to infants following birth is safe and provides high antibody levels, regardless of the mother’s RSV vaccination status, according to new research presented at
#IDWeek2025
.
bit.ly/3J9fIbS
loading . . .
RSV Immunization in Infants Is Safe and Provides High Antibody Levels Regardless of Mother’s Vaccination Status
https://bit.ly/3J9fIbS
0
7
5
reposted by
ESGREV
Vaccine Safety Initiative
4 months ago
✈️ Next stop:
#ESWI2025
in Valencia! We’re excited to join global experts in infectious disease control, antimicrobial stewardship, and vaccine innovation. Looking forward to sharing insights, forging collaborations, and advancing prevention together.
#VIVI
#InfectionPrevention
1
4
6
reposted by
ESGREV
Critical Care Reviews
4 months ago
➡️ Pediatric myocarditis is more often viral and acute, adults more chronic and immune-mediated ➡️ Diagnosis and treatment draw from adult data, leaving major gaps in paediatric evidence CCR Journal Watch - tracking the critical care literature daily
criticalcarereviews.com/latest-evide...
0
0
2
reposted by
ESGREV
Trainee Association of ESCMID
5 months ago
There are a few days left to apply for an ESCMID observership! ESCMID is awarding 50 young scientists up to 2K EUR to travel to one of the over 100 collaborative centres for knowledge exchange in the fields of CM & ID! Read more and apply before the deadline on Tuesday, 14 October:
ow.ly/95BK50X2GRP
0
0
1
reposted by
ESGREV
Trainee Association of ESCMID
5 months ago
📣🧊 The Trainee Association of ESCMID (TAE) is holding elections for 3 new members in the steering committee. Young Scientist Members (YSM) and LMIC members fulfilling the YSM criteria are eligible to apply. Nominations close 31 October.
ow.ly/fHsy50X96Nb
0
0
1
reposted by
ESGREV
Vaccine Safety Initiative
5 months ago
More than pills and shots — your gut microbiome might be a hidden key to vaccine success. 🌿 Recent research shows gut bacteria affect how well our bodies respond to
#vaccines
. Diet, probiotics, and microbiome health = new frontiers in prevention.
#Microbiome
#VIVI
1
2
3
reposted by
ESGREV
ESCMID
6 months ago
Fantastic session on vaccine licensing covering aspects from fighting ongoing outbreaks, limited clinical data, and the current latest developments in the pipeline. Featuring Marco Cavaleri, Sarah Gilbert, Teresa Lambe and Annelies Wilder-Smith.
@ema.europa.eu
#VaccinesConference
#Vaccines
#IDSky
0
4
3
reposted by
ESGREV
Vaccine Safety Initiative
6 months ago
🌍 At @ESCMID
#VaccinesConference
in Lisbon,
#Pandemic
#Preparedness
is in focus (Day 3 & Day 5). From surveillance to vaccines, global cooperation is key to staying ahead of future threats. Prevention today means resilience tomorrow.
#UnitedInProtection
👉
bit.ly/ViVI-Prep2025
0
1
3
reposted by
ESGREV
Eurosurveillance journal
6 months ago
This week's rapid communications describe ➡️A strain of Neisseria gonorrhoeae producing false negative results on Xpert CT/NG assay in England 🔎An atypical sixfold rise in
#influenza
A(H1N1)pdm09 cases in Denmark during summer Full issue here 👉
bit.ly/eus2036
#EpiSky
#IDSky
#MedSky
#STISky
🛟🦠🧫⚕️
1
9
7
reposted by
ESGREV
ImmunizeCanada
6 months ago
#JeudiRétro
| C’était la polio. Nous nous sommes fait vacciner. Éprouvés. Salvateurs. Les vaccins |
www.immunize.ca/sites/defau...
#polio
#LesVaccinsÇaMarche
#LesVaccinsSauventDesVies
#FaitesVousVacciner
loading . . .
https://www.immunize.ca/sites/default/files/because-polio-throwback-f.png
0
0
1
reposted by
ESGREV
Harvard Epidemiology
6 months ago
Welcome back students! Joining us from 29 different countries hailing from 6 continents across the various degree programs are: 72 PhD students, 15 SM1 students, 13 SM1 summer-only students, 62 SM2 students, and 76 MPH Epi students in the Department of Epidemiology
@hsph.harvard.edu
.
0
4
4
reposted by
ESGREV
Open Forum Infectious Diseases
6 months ago
Response to Letter to the Editor, Re: The Effect of Nirmatrelvir-Ritonavir on Short- and Long-term Adverse Outcomes From COVID-19 Among Patients With Kidney Disease: A Propensity Score-Matched Study ✅ Just Accepted
#IDSky
loading . . .
Response to Letter to the Editor, Re: The Effect of Nirmatrelvir-Ritonavir on Short- and Long-term Adverse Outcomes From COVID-19 Among Patients With Kidney Disease: A Propensity Score-Matched Study
https://bit.ly/3JxUxzY
1
1
3
reposted by
ESGREV
Critical Care Reviews
6 months ago
Ebola Virus Disease: Uniquely Challenging Among the Viral Hemorrhagic Fevers CCR Journal Watch - tracking the critical care literature daily
https://criticalcarereviews.com/latest-evidence/journal-watch
0
1
1
reposted by
ESGREV
Open Forum Infectious Diseases
6 months ago
Skin lesions and personal protective equipment (PPE) in healthcare workers from Lima, Peru during the COVID-19 pandemic: a cross-sectional study ✅ Just Accepted
#IDSky
loading . . .
Skin lesions and personal protective equipment (PPE) in healthcare workers from Lima, Peru during the COVID-19 pandemic: a cross-sectional study
During the COVID-19 pandemic, healthcare workers (HCWs) relied on personal protective equipment (PPE) to mitigate COVID-19 infections.
https://bit.ly/41Vvo8v
0
0
1
reposted by
ESGREV
International Society of Antimicrobial Chemotherapy
6 months ago
🧪 Just 1 week left to apply! ISAC Project Grants 2025 offer up to £15,000 for research in
#AMR
&
#infectiousdiseases
🌍 Projects must involve 2 countries (1 LMIC) 📅 Deadline: 1 Sept 📧
[email protected]
🔗
isac.world
#GlobalHealth
#ISACGrants
@heiman-wertheim.bsky.social
@souhakanj.bsky.social
0
2
3
reposted by
ESGREV
Vaccine Safety Initiative
6 months ago
Stopping Spillover at the Source:
#OneHealth
Meets
#Pandemic
#Prevention
🛎️ A new roadmap in Emerging Infectious Diseases outlines how investigating and intercepting virus spillovers early—using integrated, cross‑sector efforts (One Health approach)—can help prevent future pandemics.
#ActNow
1
2
3
reposted by
ESGREV
The Journal of Infectious Diseases
6 months ago
Accurate measurement of viral clearance in early phase antiviral studies in COVID-19 ✅ Just Accepted
#IDSky
loading . . .
Accurate measurement of viral clearance in early phase antiviral studies in COVID-19
This letter iresponds to the recent meta-analysis reported by Mateja et al. (J Infect Dis. 2025 Jun 3: jiaf282), which supports the use of SARS-CoV-2 clearance as a surrogate for clinical benefit in COVID-19, and concludes that a single post-treatment nasopharyngeal swab is sufficient to assess...
https://doi.org/10.1093/infdis/jiaf442?utm_source=bluesky&utm_medium=organic-social&utm_content=%40jidjournal.bsky.social&utm_campaign=JID-Article-Promotion
1
1
2
reposted by
ESGREV
Critical Care Reviews
6 months ago
The 715th Critical Care Reviews Newsletter is now out, covering the latest critical care publications from across the literature over the past week. Sample issue -
https://criticalcarereviews.com/newsletters/sample-newsletter
Subscribe at -
https://criticalcarereviews.com/newsletters/subscribe
0
0
1
reposted by
ESGREV
Critical Care Reviews
6 months ago
Advances in ischemic stroke treatment: current and future therapies CCR Journal Watch - tracking the critical care literature daily
https://criticalcarereviews.com/latest-evidence/journal-watch
0
1
1
reposted by
ESGREV
8 months ago
www.escmid-foundation.org/event-detail...
We are pleased to announce this Postgraduate Course co-organised by:
@escmid.bsky.social
,
#EIS
,
#ESGCIP
,
#ESGMD
,
#ESGIE
,
@esgphm.bsky.social
,
#EVASG
,
@esgrev-escmid.bsky.social
and the
#BIA
; Sevilla, Spain, 21-23/10/25. Registration will close July 15.
loading . . .
Emerging Infectious Diseases: Understanding, Prevention, and Response
https://www.escmid-foundation.org/event-detail/emerging-infectious-diseases-understanding-prevention-and-response/
0
0
1
Stay tuned for the next @ESCMID event! If you are working in vaccines and don’t want to wait until ESCMIDGlobal 2026 in Munich, then check out this vaccine conference in Lisbon in the fall this year.
add a skeleton here at some point
11 months ago
0
1
1
reposted by
ESGREV
ImmunizeCanada
11 months ago
Allez voir l’infographie créée par Immunisation Canada! | Les vaccins contre la coqueluche durant la
#grossesse
|
immunize.ca/sites/defaul...
#coqueluche
#LesVaccinsÇaMarche
#FaitesVousVacciner
0
1
2
reposted by
ESGREV
ESCMID
11 months ago
The congress may be ending today but the content can be revisited in our
#ESCMIDGlobal
replay section. All scientific sessions can be watched or rewatched on the virtual congress platform available for 6 months:
ow.ly/f6fP50VzPeU
1
7
3
reposted by
ESGREV
ESCMID
11 months ago
Last chance at the Vienna Opera House-themed photobooth this year! Create light-hearted moments with colleagues & friends dressed as classical musicians on stage using a variety of entertaining props.
#ESCMIDGlobal
#IDSky
#clinmicro
0
4
1
reposted by
ESGREV
ESCMID
11 months ago
Kick off day 4 of
#ESCMIDGlobal
2025 now in Hall 15! Join experts as they discuss how
#climatechange
is reshaping the landscape of
#infectiousdiseases
and the urgent need for adaptation strategies. See you there!
1
16
4
reposted by
ESGREV
The Journal of Infectious Diseases
11 months ago
Vaccine Effectiveness Against Influenza A(H1N1), A(H3N2), and B-Associated Hospitalizations - United States, September 1, 2023-May 31, 2024 ✅ Just Accepted ⭐ Editor's Choice
#IDSky
loading . . .
Vaccine Effectiveness Against Influenza A(H1N1), A(H3N2), and B-Associated Hospitalizations - United States, September 1, 2023-May 31, 2024
A long 2023–2024 influenza season included sustained elevated activity from December 2023–February 2024 and continued activity through May 2024.
https://doi.org/10.1093/infdis/jiaf185?utm_source=bluesky&utm_medium=organic-social&utm_content=%40jidjournal.bsky.social&utm_campaign=JID-Article-Promotion
0
4
7
reposted by
ESGREV
ESCMID
11 months ago
Join Guy Thwaites at 16:15 CEST in Hall 1 at
#ESCMIDGlobal
2025 for a deep dive into the current landscape of
#tuberculosis
treatment, exploring the urgent need for new clinical trials and the potential of host-directed therapies.
0
8
4
reposted by
ESGREV
ESCMID
11 months ago
We are kicking off
#ESCMIDGlobal
2025 with the brand-new
#EducationFriday
! Look forward to a day of educational sessions including special small group workshops covering all topics. Conclude the day by attending the
#AMR
Science-Policy Forum co-organised with the GLG!
#IDSky
#clinmicro
#MedSky
0
16
4
#ESGREV
has grown rapidly. We are proud of our new members. Please stay engaged and follow us on social media. Feel free to DM us with questions. Enjoy the remaining days of
#ESCMIDGlobal
and see you next year in Munich!
@escmid.bsky.social
@taescmid.bsky.social
11 months ago
0
4
1
reposted by
ESGREV
bioRxiv Immunology
11 months ago
Tissue-specific improvements in CD4+ T cell responses after treatment for visceral leishmaniasis.
https://www.biorxiv.org/content/10.1101/2025.04.13.648617v1
0
1
2
reposted by
ESGREV
ImmunizeCanada
11 months ago
Varicelle : ce qu’il faut savoir | Allez voir notre feuillet de renseignements informatif! |
immunize.ca/sites/defaul...
#varicelle
#LesVaccinsÇaMarche
#FaitesVousVacciner
0
0
1
reposted by
ESGREV
EUCIC European Committee of Infection Control
11 months ago
Very Nice session
@escmid.bsky.social
on how micro may help improving infection Control measures. Educational session 💪🙏
0
4
3
reposted by
ESGREV
The Journal of Infectious Diseases
11 months ago
The effect of pre-existing coronavirus antibodies on SARS-CoV-2 infection outcomes in exposed household members ✅ Just Accepted
#IDSky
loading . . .
The effect of pre-existing coronavirus antibodies on SARS-CoV-2 infection outcomes in exposed household members
We investigated the effect of pre-existing antibodies against SARS-CoV-2 and seasonal human coronaviruses on infection outcomes in Omicron BA1/2 exposed household members from January to March 2022.
https://doi.org/10.1093/infdis/jiaf172?utm_source=bluesky&utm_medium=organic-social&utm_content=%40jidjournal.bsky.social&utm_campaign=JID-Article-Promotion
0
1
5
reposted by
ESGREV
ImmunizeCanada
11 months ago
Allez voir notre collection de courtes vidéos sur
#TikTok
!
www.tiktok.com/@immunizedot...
#LesVaccinsÇaMarche
#FaitesVousVacciner
loading . . .
Immunize Canada's Creator Profile
https://www.tiktok.com/@immunizedotca?lang=fr
0
0
1
reposted by
ESGREV
Oliver Cornely
11 months ago
Great day at the ESCMID Global 2025 in Vienna! Inspiring talks, impressive posters, and a strong presence from our team – proud of the great work and presentation. Looking forward to another exciting day tomorrow!
#ESCMID2025
#Teamwork
1
11
2
reposted by
ESGREV
ESCMID
11 months ago
Soon to come in Hall 16, don’t miss the session "Developing guidelines with AI tools: Are they ready for prime time?". Discover how
#ArtificialIntelligence
could transform the way we create patient-centered guidelines. Be there!
#ESCMIDGlobal
2025.
1
10
2
reposted by
ESGREV
Society of Infectious Diseases Pharmacists - SIDP
11 months ago
Looking for the hot trials that may change your practice at
#ESCMIDGlobal2025
? Dr.
@steventong.bsky.social
has you covered as he shares findings from the
#SNAP
Trial 💊 Among 281 pts w/ PCN-susceptible S. aureus BSI, compared to flucloxacillin, benzylpenicillin had lower 90-day mortality & less AKI
1
15
12
reposted by
ESGREV
Clinical Infectious Diseases
11 months ago
Cost-Effectiveness of One-time Universal Testing for Hepatitis D among Adults living with Chronic Hepatitis B in the United States ✅ Just Accepted
#IDSky
loading . . .
Cost-Effectiveness of One-time Universal Testing for Hepatitis D among Adults living with Chronic Hepatitis B in the United States
Chronic hepatitis D virus (HDV) infection increases the risk of liver-related deaths in adults with chronic hepatitis B (CHB).
https://doi.org/10.1093/cid/ciaf181?utm_source=bluesky&utm_medium=organic-social&utm_content=%40cidjournal.bsky.social&utm_campaign=CID-Article-Promotion
0
3
4
reposted by
ESGREV
ESCMID
11 months ago
Following
#EducationFriday
, we are excited to open up
#ESCMIDGlobal
2025 in full today! We hope you enjoy the start of the full congress today and we look forward to seeing you over the next four days in Vienna and online!
0
8
1
reposted by
ESGREV
Ecraid
11 months ago
👉🏽Day 1 at ESCMID Global - what a great start! We had interesting conversations, looking forward to more connections tomorrow at Booth E70, Hall B. Don’t miss out some great sessions tomorrow such as 'New tools in acute bacterial infections and sepsis' presented by
@lenniederde.bsky.social
.
1
3
3
Load more
feeds!
log in